AIM: The clinical significance of co-infection of SENV-D among patients with chronic hepatitis C (CHC) and response of both viruses to combination therapy with high-dose interferon-alfa (IFN) plus ribavirin remai...AIM: The clinical significance of co-infection of SENV-D among patients with chronic hepatitis C (CHC) and response of both viruses to combination therapy with high-dose interferon-alfa (IFN) plus ribavirin remain uncertain and are being investigated.METHODS: Total 164 (97 males and 67 females, the mean age 48.1+11.4 years, range: 20-73 years, 128 histologically proved) naive CHC patients were enrolled in this study. SENV-D DNA was tested by PCR method.Detection of serum HCV RNA was performed using a standardized automated qualitative RT-PCR assay (COBAS AMPLICOR HCV Test, version 2.0). HCV genotypes la,lb, 2a, 2b, and 3a were determined by using genotypespecific primers. Pretreatment HCV RNA levels were determined by using the branched DNA assay (Quantiplex HCV RNA 3.0). There are 156 patients receiving combination therapy with IFN 6 MU plus ribavirin for 24 wk and the response to therapy is determined.RESULTS: Sixty-one (37.2%) patients were positive for SENV-D DNA and had higher mean age than those who were negative (50.7+ 10.6 years vs 46.6+ 11.6 years,P = 0.026). The rate of sustained viral response (SVR) for HCV and SENV-D were 67.3% (105/156) and 56.3% (27/48), respectively. By univariate analysis, the higher rate of SVR was significantly related to HCV genotype non-1b (P〈0.001), younger ages (P = 0.014), lower pretreatment levels of HCV RNA (P = 0.019) and higher histological activity index (HAI) score for intralobular regeneration and focal necrosis (P= 0.037). By multivariate analyses, HCV genotype non-lb, younger age and lower pretreatment HCV RNA levels were significantly associated with HCV SVR (odds ratio (OR)/95% confidence interval (CI): 12.098/0.02-0.19, 0.936/0.890-0.998, and 3.131/1.080-9.077, respectively). The SVR of SENV-D was higher among patients clearing SENV-D than those who had viremia at the end of therapy (P = 0.04).CONCLUSION: Coexistent SENV-D infection, apparently associated with higher ages, is found in more than onethird Taiwan Residents CHC patients. Both HCV and SENV-D are highly susceptible to combination therapy with high-dose IFN and ribavirin and SENV-D co-infection does not affect the HCV response. HCV genotype, pretreatment HCV RNA levels and age are predictive factors for HCV SVR.展开更多
OBJECTIVE: To investigate the effects of the Sini San at different doses on each sleeping state[slow-wave sleep 1(SWS1), slow-wave sleep 2(SWS2), rapid-eye-movement(REM), wakefulness(W)] in insomnia rats and to identi...OBJECTIVE: To investigate the effects of the Sini San at different doses on each sleeping state[slow-wave sleep 1(SWS1), slow-wave sleep 2(SWS2), rapid-eye-movement(REM), wakefulness(W)] in insomnia rats and to identify its mode of ac-tion for improving sleep.METHODS: The insomnia rats were randomly divided into a high-, medium- or low-dose group of Sini San(equal to crude drug 8.8, 4.4, or 2.2 g/kg, respectively) for seven consecutive days.RESULTS: Compared with pre-administration,SWS2 was significantly increased after administration of the low dose. Compared with pre-administration, W was significantly decreased and SWS1,SWS2, and the total sleeping time(TST) were markedly increased after administration of the medium dose. Compared with pre-administration, W was significantly decreased and SWS1, SWS2, rapid-eye-movement sleep, and TST were significantly longer after administration of the high dose. The effects of Sini San on sleep-wake cycle are dose-dependent.CONCLUSION: The results suggest that Sini San extends SWS1 and SWS2, which increases the total sleeping time.展开更多
基金Supported by the National Science Council Grant, No. NSC-91-2314-B037-344
文摘AIM: The clinical significance of co-infection of SENV-D among patients with chronic hepatitis C (CHC) and response of both viruses to combination therapy with high-dose interferon-alfa (IFN) plus ribavirin remain uncertain and are being investigated.METHODS: Total 164 (97 males and 67 females, the mean age 48.1+11.4 years, range: 20-73 years, 128 histologically proved) naive CHC patients were enrolled in this study. SENV-D DNA was tested by PCR method.Detection of serum HCV RNA was performed using a standardized automated qualitative RT-PCR assay (COBAS AMPLICOR HCV Test, version 2.0). HCV genotypes la,lb, 2a, 2b, and 3a were determined by using genotypespecific primers. Pretreatment HCV RNA levels were determined by using the branched DNA assay (Quantiplex HCV RNA 3.0). There are 156 patients receiving combination therapy with IFN 6 MU plus ribavirin for 24 wk and the response to therapy is determined.RESULTS: Sixty-one (37.2%) patients were positive for SENV-D DNA and had higher mean age than those who were negative (50.7+ 10.6 years vs 46.6+ 11.6 years,P = 0.026). The rate of sustained viral response (SVR) for HCV and SENV-D were 67.3% (105/156) and 56.3% (27/48), respectively. By univariate analysis, the higher rate of SVR was significantly related to HCV genotype non-1b (P〈0.001), younger ages (P = 0.014), lower pretreatment levels of HCV RNA (P = 0.019) and higher histological activity index (HAI) score for intralobular regeneration and focal necrosis (P= 0.037). By multivariate analyses, HCV genotype non-lb, younger age and lower pretreatment HCV RNA levels were significantly associated with HCV SVR (odds ratio (OR)/95% confidence interval (CI): 12.098/0.02-0.19, 0.936/0.890-0.998, and 3.131/1.080-9.077, respectively). The SVR of SENV-D was higher among patients clearing SENV-D than those who had viremia at the end of therapy (P = 0.04).CONCLUSION: Coexistent SENV-D infection, apparently associated with higher ages, is found in more than onethird Taiwan Residents CHC patients. Both HCV and SENV-D are highly susceptible to combination therapy with high-dose IFN and ribavirin and SENV-D co-infection does not affect the HCV response. HCV genotype, pretreatment HCV RNA levels and age are predictive factors for HCV SVR.
基金Supported by Hippocampus Neural Coding Mechanism Research on Sini San Intervention Sleep Disorders of PTSD in Myospalax cansus from the National Natural Science Foundation(No.81460611)Study on Sini San for regulation of expression of proteins of drosophila brain of sleep deprivation of Gansu Province Natural Science Foundation(No.145RJZA076)+3 种基金Fundamental Research Funds for the Gansu Provincial Department of Finance Universities(No.2013-2)Mechanisms of hippocampal neurons based on Jiawei Sini San intervention coding mode PTSD sleep disordersMinistry of Education,Sini San for intervention of sleep deprivation in drosophila Based nano-2D-LC/MS technology of Science and Technology Key Project(No.212186)Proteomics and effective substance basic of Sini San for improving sleep of Gansu Province Natural Science Foundation(No.1010RJZA212)
文摘OBJECTIVE: To investigate the effects of the Sini San at different doses on each sleeping state[slow-wave sleep 1(SWS1), slow-wave sleep 2(SWS2), rapid-eye-movement(REM), wakefulness(W)] in insomnia rats and to identify its mode of ac-tion for improving sleep.METHODS: The insomnia rats were randomly divided into a high-, medium- or low-dose group of Sini San(equal to crude drug 8.8, 4.4, or 2.2 g/kg, respectively) for seven consecutive days.RESULTS: Compared with pre-administration,SWS2 was significantly increased after administration of the low dose. Compared with pre-administration, W was significantly decreased and SWS1,SWS2, and the total sleeping time(TST) were markedly increased after administration of the medium dose. Compared with pre-administration, W was significantly decreased and SWS1, SWS2, rapid-eye-movement sleep, and TST were significantly longer after administration of the high dose. The effects of Sini San on sleep-wake cycle are dose-dependent.CONCLUSION: The results suggest that Sini San extends SWS1 and SWS2, which increases the total sleeping time.